Marc B. Garnick, M.D.

Marc B. Garnick, M.D., is an internationally renowned expert in medical oncology and urologic cancer. A clinical professor of medicine at Harvard Medical School, he also maintains an active clinical practice at Beth Israel Deaconess Medical Center. He has dedicated his career to the development of new therapies for the treatment of prostate cancer. Dr. Garnick is the Editor in Chief of HarvardProstateKnowledge.org and Harvard Medical School's Annual Report on Prostate Diseases, both of which emerged from his keen interest in explaining issues of medical importance to patients and their families to help them make appropriate treatment choices.


Posts by Marc B. Garnick, M.D.

Do all BPH drugs reduce semen production?

Marc B. Garnick, M.D.

Editor in Chief, HarvardProstateKnowledge.org

I have used finasteride (Proscar) to treat my BPH, and it has reduced the size of my prostate. However, my body’s production of semen has diminished, too. Will switching to dutasteride (Avodart) solve that problem?

Hormone therapy for prostate cancer

Marc B. Garnick, M.D.

Editor in Chief, HarvardProstateKnowledge.org

Marc Garnick, M.D., Editor in Chief of the Annual Report on Prostate Diseases, discusses what you need to know about therapy: when it’s used, what your options are, and what doctors disagree about.

Early-stage prostate cancer: Treat or wait?

Marc B. Garnick, M.D.

Editor in Chief, HarvardProstateKnowledge.org

When it comes to early-stage prostate cancer, there is no evidence that one treatment is better than another or that any treatment at all actually prolongs life. If you are diagnosed with early-stage prostate cancer, you’ll want to consider factors such as your values, your quality of life, and the potential side effects of various treatments before making a decision.

Finding help for pelvic pain: A patient’s story

Marc B. Garnick, M.D.

Editor in Chief, HarvardProstateKnowledge.org

Patient